Full-Time

Validation Engineer 2

Updated on 8/1/2026

Replimune Group

Replimune Group

201-500 employees

Develops oncolytic viral immunotherapies for cancer

Compensation Overview

$137k - $177k/yr

+ Annual performance incentive bonus + New hire equity + Ongoing performance-based equity

Framingham, MA, USA

In Person

Five days on-site per week are typically expected.

Category
QA & Testing (1)
Required Skills
GMP

Get referred to Replimune Group

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific, engineering, or similar subject is required.
  • A minimum of five years of professional experience in validation, engineering, or operations is required.
  • Experience with Good Manufacturing Practice utilities and equipment is required.
  • Excellent communication and interpersonal skills are required.
  • Attention to detail, flexibility, and technical writing skills are required.
  • Knowledge of current Good Manufacturing Practice and Good Documentation Practice requirements is required.
  • The ability to work independently or in a team environment, remain self-motivated, and show initiative is required.
Responsibilities
  • Conduct impact and risk assessments and support the development of user requirement specifications as needed.
  • Author qualification, validation, and revalidation protocols and reports for facilities, equipment, and critical utilities.
  • Ensure validation documentation complies with industry standards, approved procedures, and current regulatory requirements.
  • Independently execute validation activities with limited supervision while identifying, communicating, and escalating project risks and compliance concerns as appropriate.
  • Coordinate the scheduling, execution, and review of qualification and validation protocols and reports.
  • Coordinate and oversee vendors and contractors performing qualification activities.
  • Collaborate with Engineering, Manufacturing, Quality Assurance, and other functional areas to support validation and qualification activities.
  • Review, revise, and complete documentation in accordance with current Good Manufacturing Practice and Good Documentation Practice.
  • Support change controls and deviations by performing impact assessments related to the validated status of utilities, equipment, instruments, and systems.
  • Assist with troubleshooting equipment and system failures and support investigations as required.
  • Perform other assigned duties and projects.
  • Perform work in accordance with Standard Operating Procedures, current Good Manufacturing Practices, quality standards, and safety procedures.
  • Support equipment- and process-related nonconformance investigations and change-control activities.
  • Assist with internal and regulatory agency audits and inspections.
  • Ensure training remains in a Good Manufacturing Practice-compliant state.
Desired Qualifications
  • A Master of Science degree is preferred.
  • A minimum of three years of relevant experience in a current Good Manufacturing Practice environment is preferred.

Replimune develops cancer therapies that use engineered viruses (oncolytic immunotherapies) to attack tumors. These treatments selectively infect cancer cells, causing their destruction, and at the same time stimulate the immune system to recognize and fight tumors. By combining multiple methods of action, Replimune aims to boost the effectiveness of existing immune checkpoint inhibitors and create a stronger anti-tumor response. The company focuses on research, development, and clinical testing, and plans to earn revenue through partnerships, licensing, and eventual sales of approved therapies. Its goal is to deliver workable cancer treatments by validating safety and efficacy in clinical trials and bringing these therapies to patients with various cancers.

Company Size

201-500

Company Stage

IPO

Headquarters

Woburn, Massachusetts

Founded

2015

Get referred to Replimune Group

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • RP2-202 randomized Phase 2/3 trial enrolls ~280 patients in checkpoint-naïve uveal melanoma, addressing critical unmet need.
  • RP2 FIH data showed 33.3% pooled ORR in uveal melanoma with durable responses up to 27.3+ months.
  • RP2 reprograms cold tumors to immune-inflamed, expanding TCR clones and confirming systemic immune engagement mechanism.

What critics are saying

  • Second FDA rejection of RP1 due to inadequate trial design caused 224 job cuts and $269M cash runway risk.
  • Class action lawsuits for securities fraud tied to FDA rejections expose legal liability and reputational damage.
  • RP2 Phase 2/3 approval may be delayed or denied if FDA applies same 'not well-controlled' scrutiny as RP1.

What makes Replimune Group unique

  • RP2 adds anti-CTLA-4 molecule and GM-CSF to HSV-1, enhancing tumor killing and systemic immune response.
  • RPx platform enables dual local tumor killing and systemic T-cell activation, overcoming checkpoint inhibitor resistance.
  • Focus on rare uveal melanoma and HCC with unmet needs, positioning RP2 as a potential new standard of care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Performance Bonus

Company Equity

Growth & Insights

Headcount

6 month growth

11%

1 year growth

14%

2 year growth

14%